** Structure Therapeutics shares GPCR.O up about 3% at $61.80

** Eli Lilly LLY.N trial data shows its oral pill, orforglipron, helped patients maintain weight loss after switching from injectable GLP-1 drugs

** J.P. Morgan says Lilly's data "is a good read-across" for GPCR's oral pill, aleniglipron, whose trial data is due H2 2026

** GPCR shares had doubled on Dec 8 after aleni trial data showed weight loss of up to 11.3% after 36 weeks of treatment

** Stock now up about 126% YTD, after a 33.5% drop in 2024

** JPM thinks both orfo and aleni could be effective options for patients who want to move away from injectables long term

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))